Dopamine, immunity, and disease
B Channer, SM Matt, EA Nickoloff-Bybel, V Pappa… - Pharmacological …, 2023 - Elsevier
The neurotransmitter dopamine is a key factor in central nervous system (CNS) function,
regulating many processes including reward, movement, and cognition. Dopamine also …
regulating many processes including reward, movement, and cognition. Dopamine also …
[HTML][HTML] The bidirectional relationship of depression and inflammation: double trouble
Depression represents the number one cause of disability worldwide and is often fatal.
Inflammatory processes have been implicated in the pathophysiology of depression. It is …
Inflammatory processes have been implicated in the pathophysiology of depression. It is …
The promise of machine learning in predicting treatment outcomes in psychiatry
For many years, psychiatrists have tried to understand factors involved in response to
medications or psychotherapies, in order to personalize their treatment choices. There is …
medications or psychotherapies, in order to personalize their treatment choices. There is …
Prognosis and improved outcomes in major depression: a review
Abstract Treatment outcomes for major depressive disorder (MDD) need to be improved.
Presently, no clinically relevant tools have been established for stratifying subgroups or …
Presently, no clinically relevant tools have been established for stratifying subgroups or …
Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta …
F Milosavljević, N Bukvić, Z Pavlović, Č Miljević… - JAMA …, 2021 - jamanetwork.com
Importance Precise estimation of the drug metabolism capacity for individual patients is
crucial for adequate dose personalization. Objective To quantify the difference in the …
crucial for adequate dose personalization. Objective To quantify the difference in the …
Review and consensus on pharmacogenomic testing in psychiatry
The implementation of pharmacogenomic (PGx) testing in psychiatry remains modest, in part
due to divergent perceptions of the quality and completeness of the evidence base and …
due to divergent perceptions of the quality and completeness of the evidence base and …
[HTML][HTML] Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient-and rater-blinded, randomized, controlled …
Current prescribing practices for major depressive disorder (MDD) produce limited treatment
success. Although pharmacogenomics may improve outcomes by identifying genetically …
success. Although pharmacogenomics may improve outcomes by identifying genetically …
The state of our understanding of the pathophysiology and optimal treatment of depression: glass half full or half empty?
CB Nemeroff - American Journal of Psychiatry, 2020 - Am Psychiatric Assoc
Major depressive disorder is a remarkably common and often severe psychiatric disorder
associated with high levels of morbidity and mortality. Patients with major depression are …
associated with high levels of morbidity and mortality. Patients with major depression are …
Association between systemic inflammation and individual symptoms of depression: a pooled analysis of 15 population-based cohort studies
Objective: Evidence from anti-inflammatory drug trials for the treatment of depression has
been inconsistent. This may be ascribed to the differing symptom-specific effects of …
been inconsistent. This may be ascribed to the differing symptom-specific effects of …
Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials
Aim: To conducted a systematic review and meta-analysis of prospective, randomized
controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools …
controlled trials (RCTs) that examined pharmacogenetic-guided decision support tools …